Pot stocks have always been an interesting sector to discuss, given the vast amount of speculations, unexpected returns, high risk and a lot of future uncertainties. Let us have a look at some of the pot stocks listed on ASX.
TPI Enterprises Limited (ASX: TPE)
TPI Enterprises Limited works in the healthcare sector and is one of the few poppy processors in Australia. It produces Narcotic Raw Material (NRM) for the global healthcare industry. It is expanding into Australia, and Europe ensuring long term sustainability.
In the financial results for 1HFY19, the company reported a statutory loss of $5.78 million which is relatively better than the $16.69 million statutory loss in 1HFY18. EBITDA also improved from negative $11.88 million to negative $2.56 million in the same period.
In the recent 2018 annual report announced on 26th April 2019, the company updated about the original debt facility compared with the updated one. The original facility was of $8 million with 10.0% p.a. on drawn funds. The amended facility was of $25.0 million with 11.0% p.a. on drawn funds up to $16.4 million, 9.0% p.a. on drawn funds over $16.4 million
The stock of the company last traded at A$1.345 as on 26 April 2019. The market capitalisation of the company is A$109.06 million with 52-week high and low of A$1.64 and A$0.900 respectively. The YTD return of the stock is 11.16%.
EVE Investments Limited (ASX: EVE)
EVE Investments Limited is in the financial sector, and it specifically invests in the companies having a primary interest in the field of Health, Nutrition and Wellness. One of the company’s 100% owned investments is Meluka Health and Jenbrook Pty Ltd. Meluka heath is a wellness and nutrition company which further owns several brands like Meluka Honey, Meluka Essentials etc.
In its latest Hong Kong and Singapore roadshow presentation, the company discussed the Global Essential Oil Market, which is expected to reach $14.28 billion by 2025, at a growth rate of 8.5% CAGR from 2018 – 2025, which depicts huge opportunity for Meluka Essentials.
In the half-year result for the period ended 31st December 2018, the company posted revenue of $955,543, and no dividends were declared. The loss for the half-year duration was noted at $1.31 million. The total asset of $7.77 million and total liabilities of $1.38 million was reported in the balance sheet as on 31st December 2018.
The stock of the company last traded at A$0.006 as on 26 April 2019. The market capitalisation of the company is A$11.88 million with 52-week high and low of A$0.014 and A$0.004 respectively. The YTD return of the stock is 16.67%.
Zelda Therapeutics Ltd (ASX: ZLD)
Zelda Therapeutics Ltd is a healthcare company having an interest in the medical cannabis market. It operates in Australia, the United States and Chile and working on treating medical conditions like insomnia, autism etc.
Recently, the company entered into a partnership with US-based medical cannabis company, Ilera HealthCare to explore a broad range of commercialisation opportunities. It will position the company for rapid commercialisation of its clinically-validated products.
In the 1HFY19 results, the company reported revenue from operating activities at A$47,714 and total loss for the period stood at $2.06 million. Consequently, loss per share widened to 0.27 cents per share (cps) from 0.07 cps. Total assets were reported significantly higher at 4.84 million compared to the total liabilities of $576,857.
The stock of the company last traded at A$0.045 as on 26 April 2019. The market capitalisation of the company is A$36.26 million with 52-week high and low of A$0.130 and A$0.033 respectively. The YTD return of the stock is 17.24%.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.